argenx SE (NASDAQ:ARGX) Stake Reduced by Fiera Capital Corp

Fiera Capital Corp reduced its holdings in argenx SE (NASDAQ:ARGX) by 4.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,353 shares of the company’s stock after selling 7,242 shares during the quarter. Fiera Capital Corp owned 0.26% of argenx worth $85,840,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. J.Safra Asset Management Corp grew its stake in argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after acquiring an additional 59 shares in the last quarter. Blue Trust Inc. increased its stake in argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after buying an additional 62 shares during the period. GAMMA Investing LLC increased its stake in argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after buying an additional 40 shares during the period. Cromwell Holdings LLC lifted its position in argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after buying an additional 66 shares in the last quarter. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of argenx during the 2nd quarter valued at $76,000. 60.32% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ARGX has been the topic of a number of recent research reports. Scotiabank upgraded argenx from a “sector perform” rating to a “sector outperform” rating and boosted their target price for the company from $439.00 to $715.00 in a research note on Tuesday. Evercore ISI boosted their price target on argenx from $478.00 to $533.00 and gave the company an “outperform” rating in a research note on Friday, July 12th. Baird R W lowered shares of argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. HC Wainwright boosted their target price on shares of argenx from $533.00 to $617.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Finally, JMP Securities raised their price target on shares of argenx from $497.00 to $606.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $615.50.

argenx Stock Performance

Shares of ARGX traded up $3.20 during trading hours on Friday, reaching $594.64. 83,429 shares of the company traded hands, compared to its average volume of 307,393. argenx SE has a 1-year low of $327.73 and a 1-year high of $611.22. The stock has a market cap of $35.56 billion, a P/E ratio of -672.09 and a beta of 0.61. The stock’s fifty day moving average is $545.48 and its 200 day moving average is $472.18.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating the consensus estimate of $0.10 by $1.29. The firm had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter in the prior year, the firm posted ($1.25) EPS. On average, equities research analysts predict that argenx SE will post 2.2 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.